The Kaiser Family Foundation maintains an ongoing tracker of federal Medicaid program integrity developments and their state-specific implications. The resource documents CMS enforcement actions, audit findings, and compliance initiatives as they emerge across different states. The tracker serves as a reference for monitoring federal oversight activity affecting state Medicaid programs. It compiles information on federal actions rather than reporting a single policy change or rulemaking.
Why it mattersManaged care organizations need to monitor federal program integrity trends to anticipate heightened scrutiny, audit focus areas, and potential state-level compliance requirements that could affect MCO operations and reporting obligations.
Managed Care · Finance
A bipartisan bill in Congress would end the requirement that methadone for opioid use disorder be dispensed only through specialty opioid treatment programs, allowing qualified practitioners to prescribe it directly like buprenorphine. The legislation would enable office-based prescribing and pharmacy dispensing of methadone, dramatically expanding access beyond the current clinic-only model. If enacted, the change would remove a longstanding barrier to medication-assisted treatment that has limited access particularly in rural and underserved areas. The timing and specific requirements for prescriber qualifications remain unclear pending legislative details.
Why it mattersMedicaid managed care organizations would need to credential new methadone prescribers, establish pharmacy networks capable of dispensing methadone, update prior authorization protocols, and potentially renegotiate rates as treatment shifts from specialized clinics to office-based settings.
Behavioral Health · Managed Care · Pharmacy
CMS projects national home health care spending will grow 7.9% in 2026, down from 10.3% in 2025, according to a Health Affairs report on national health expenditure projections. The deceleration reflects moderating post-pandemic utilization trends while still indicating strong growth in the home health sector. The projections cover total national home health spending across all payers, including Medicare, Medicaid, and commercial insurance. For Medicaid managed care organizations with home health benefit responsibility or LTSS carve-ins, the projections signal continued upward pressure on capitated rates and medical expense ratios in the home health category.
Why it mattersSustained high home health spending growth will drive capitation rate negotiations and medical loss ratio management for MCOs covering home health benefits or LTSS services delivered in home settings.
LTSS · Managed Care · Finance
CMS actuaries project total U.S. health spending will reach $5.7 trillion in 2025, with growth primarily driven by increased utilization rather than unit cost increases. Prescription drug spending is accelerating sharply, particularly for GLP-1 medications used for diabetes and weight management. The utilization trend affects all payers including Medicaid managed care plans, which face rising pharmacy costs and member demand for high-cost specialty drugs. CMS expects spending growth to moderate in subsequent years as utilization patterns stabilize.
Why it mattersRising utilization of high-cost drugs like GLP-1s will pressure MCO pharmacy budgets and may trigger mid-year capitation rate adjustments if state actuaries did not adequately account for this trend in rate development.
Pharmacy · Managed Care · Finance
Senator Bill Cassidy has introduced legislation to restrict eligibility for the 340B drug discount program, which allows certain hospitals and health centers to purchase outpatient drugs at steep discounts. The proposal comes as hospitals face broader federal funding pressures. While specific provisions are not detailed in the brief article, any 340B restrictions typically target hospital eligibility criteria, contract pharmacy arrangements, or program oversight. The timing is significant as hospitals already navigate budget constraints and prior 340B enforcement actions.
Why it mattersMedicaid MCOs reimburse 340B-eligible hospitals at higher rates for drugs purchased at discount, creating budget pressures and rate-setting complexities if eligibility rules change.
Pharmacy · Managed Care